EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Tafamidis Reduces Death and Hospitalization for Acute Heart Failure in Octogenarian Patients With Transthyretin Cardiac Amyloidosis: A Propensity Score–Weighted Cohort Study

Louise Zmuda, Amira Zaroui, Mounira Kharoubi iD, Emmanuelle Boutin, Frédéric Roca iD, Silvia Oghina iD, Emmanuel Teiger iD, Marie Laurent, Florence Canoui-Poitrine iD, Thibaud Damy iD, Amaury Broussier iD

Journal of the American Heart Association · 16.12.2025 · 14 (24)

DOI: 10.1161/jaha.125.042330 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of the American Heart Association, erschienen am 16.12.2025. Verfasst von Louise Zmuda und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Heart Failure and Amyloidosis Unit and Referral Center for Cardiac Amyloidosis AP-HP, Hopitaux Henri-Mondor Creteil France. Hauptthemen laut MEDLINE: Heart Failure, Amyloid Neuropathies, Familial, Benzoxazoles, Cardiomyopathies. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Transthyretin cardiac amyloidosis results from the deposition of misfolded amyloid fibrils in cardiac tissue, leading to progressive heart failure. Tafamidis, a transthyretin stabilizer, reduces all‐cause death and cardiovascular rehospitalization, but its impact on people aged ≥80 years remains underexplored. This study evaluated the effectiveness of tafamidis in octogenarian patients with transthyretin cardiac amyloidosis compared with nonexposed patients.

Methods

A propensity score–weighted cohort study included all patients aged ≥80 years with confirmed transthyretin cardiac amyloidosis (hereditary or wild‐type) followed at the French Referral Center for cardiac amyloidosis between 2010 and 2021. Patients who initiated tafamidis after November 1, 2018, and were treated for at least 24 months were included in the tafamidis group, whereas patients diagnosed between March 18, 2010, and November 1, 2018, who did not receive tafamidis were included in the nonexposed group. The primary outcome was 24‐month all‐cause death, and the secondary outcomes were hospital readmission for acute heart failure at 12 months and the causes of death.

Results

Between March 18, 2010, and July 5, 2021, 465 patients were included. After inverse probability of treatment weighting, tafamidis treatment was found to be associated with a relative reduction of 56% in the 24‐month mortality rate (hazard ratio [HR], [95% CI, 0.44 0.35–0.57]; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureAmyloid Neuropathies, FamilialBenzoxazolesCardiomyopathiesHospitalizationHumansAged, 80 and overMaleFemalePropensity ScorePatient ReadmissionRetrospective StudiesTreatment OutcomeAcute DiseaseFranceCause of Death

Stichwörter der Autor:innen

ATTR‐CAheart failureolder adultstafamidistransthyretin

Substanzen

tafamidisBenzoxazoles

Autor:innen und Institutionen

  • Department of Cardiology, Heart Failure and Amyloidosis Unit and Referral Center for Cardiac Amyloidosis AP-HP, Hopitaux Henri-Mondor Creteil France.
  • Department of Geriatric Medicine Rouen University Medical Center Rouen France.
  • INSERM U1096 Normandy University, UniRouen Rouen France.
  • Department of Pharmacology Rouen University Medical Center Rouen France.
  • Univ Paris Est Creteil, INSERM, IMRB Creteil France.
  • Unité de Recherche Clinique (URC Mondor), AP-HP Hôpitaux Universitaires Henri Mondor Créteil France.

ORCID-Profile: Mounira Kharoubi, Frédéric Roca, Silvia Oghina, Emmanuel Teiger, Florence Canoui-Poitrine, Thibaud Damy, Amaury Broussier

Zitieren

APA

Zmuda, L., Zaroui, A., Kharoubi, M., Boutin, E., Roca, F., Oghina, S., Teiger, E., Laurent, M., Canoui-Poitrine, F., Damy, T., & Broussier, A. (2025). Tafamidis Reduces Death and Hospitalization for Acute Heart Failure in Octogenarian Patients With Transthyretin Cardiac Amyloidosis: A Propensity Score–Weighted Cohort Study. Journal of the American Heart Association, 14(24). https://doi.org/10.1161/jaha.125.042330

Vancouver

Zmuda L, Zaroui A, Kharoubi M, Boutin E, Roca F, Oghina S, et al. Tafamidis Reduces Death and Hospitalization for Acute Heart Failure in Octogenarian Patients With Transthyretin Cardiac Amyloidosis: A Propensity Score–Weighted Cohort Study. Journal of the American Heart Association. 2025;14(24). doi:10.1161/jaha.125.042330

BibTeX
@article{Zmuda2025,
  author = {Zmuda, Louise and Zaroui, Amira and Kharoubi, Mounira and Boutin, Emmanuelle and Roca, Frédéric and Oghina, Silvia and Teiger, Emmanuel and Laurent, Marie and Canoui-Poitrine, Florence and Damy, Thibaud and Broussier, Amaury},
  title = {Tafamidis Reduces Death and Hospitalization for Acute Heart Failure in Octogenarian Patients With Transthyretin Cardiac Amyloidosis: A Propensity Score–Weighted Cohort Study},
  journal = {Journal of the American Heart Association},
  year = {2025},
  volume = {14},
  number = {24},
  doi = {10.1161/jaha.125.042330}
}
Kostenlos starten →